The global Minimal Residual Disease (MRD) market size was USD 1,095.3 Million in 2021 and is expected to register a revenue CAGR of 16.04% during the forecast period, according to the latest analysis by Emergen Research. Rising R&D activities and increase in research funding from various cancer institutes are major factors projected to support market revenue growth between 2021 and 2030. For instance, Invitae Corporation, based in the U.S., started a research in February 2022 to collect actual data on tailored minimal residual disease diagnostics for distinct tumor types. Inivata also introduced RaDaR assay in April 2020 to identify and track residual disease and relapse in plasma samples of patients with prior cancer diagnoses. In addition, RaDaR assay is based on next-generation sequencing platform InVision liquid biopsy, developed by Inivata, which has built-in control and error checking for highly sensitive and precise variant detection. Moreover, to improve testing and detection outcomes, companies competing in the worldwide MRD testing market are concentrating more on disease-specific and tailored diagnostic kits, which is also expected to drive revenue growth of the market.
The report studies the historical data of the Minimal Residual Disease market and offers valuable information about the key segments and sub-segments, revenue generation, demand and supply scenario, trends, and other vital aspects. The report offers an accurate forecast estimation of the Minimal Residual Disease industry based on the recent technological and research advancements. It also offers valuable data to assist the investors in formulating strategic business investment plans and capitalize on the emerging growth prospects in the Minimal Residual Disease market.
The global Minimal Residual Disease industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.
The leading market contenders listed in the report are:
Adaptive Biotechnologies, ARUP Laboratories, Bio-Rad Laboratories, Inc., Cergentis B.V., F. Hoffmann-La Roche Ltd., ICON Plc, Invivoscribe, Inc., Laboratory Corporation of America Holdings, Mission Bio, Natera, Inc., NeoGenomics Laboratories, OPKO Health, Inc., and Sysmex Corporation
Key market aspects studied in the report:
Market Scope: The report explains the scope of various commercial possibilities in the global Minimal Residual Disease market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.
Competitive Outlook: The leading companies operating in the Minimal Residual Disease market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.
Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Minimal Residual Disease market.
Market Segmentations of the Minimal Residual Disease Market
This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Minimal Residual Disease market on the basis of product, application, and region:
Segments Covered in this report are:
Indication Outlook (Revenue, USD Million; 2019–2030)
Leukemia
Acute Lymphoblastic Leukemia (ALL)
Chronic Lymphoblastic Leukemia (CLL)
Acute Myeloid Leukemia (AML)
Chronic Myeloid Leukemia (CML)
Others
Lymphoma
Non-Hodgkin’s Lymphoma (NHL)
Marginal Zone Lymphoma
Follicular Lymphoma
Peripheral T-cell Lymphoma
Mantle Cell Lymphoma
Others
Multiple Myeloma (MM)
Solid Tumor
Others
Detection Outlook (Revenue, USD Million; 2019–2030)
Next-Generation Sequencing (NGS)
Flow Cytometry
Polymerase Chain Reaction (PCR)
Fluorescence In-Situ Hybridization (FISH)
Others
Treatment Methods Outlook (Revenue, USD Million; 2019–2030)
